As Hepatitis B, Hepatitis C, and HIV) from unsafe injection practices, and use of propofol vials intended for single use on

During monitored anesthesia care (MAC) sedation, attention must be given to the cardiorespiratory effects of propofol injectable

Intravenous injection of a therapeutic dose of propofol induces hypnosis, with minimal excitation, usually within 40 seconds

The pharmacokinetics of propofol were studied in children between 3 and 12 years of age who received propofol injectable emulsion

This does not appear to be an age-related change in pharmacodynamics or brain sensitivity, as measured by EEG burst suppression.

With increasing patient age, the dose of propofol needed to achieve a defined anesthetic end point (dose-requirement) decreases.

Although a causal relationship is unknown.

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

Anesthesia and MAC Sedation in Adults

Many patients will arise from this phase with a sense of disorientation, amnesia, and occasionally hypothermia.

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

- Bradycardia
- Pruritus [Peds: 2%]

In clinical trials which included cardiac surgical patients, most patients were 3 years of age or older. The ranges of ages in each study were:

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

- Bradycardia
- Pruritus [Peds: 2%]

In clinical trials which included cardiac surgical patients, most patients were 3 years of age or older. The ranges of ages in each study were:

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established

The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established
Warning: Less Than 75% - Probability: Causally Related

**WARNINGS**

**Drugs and Alcohol**

**Induction**

- Induction 0.5 to 1.5 mg/kg over 60 sec

**Preinduction**

- Allow approximately 2 minutes for onset of peak drug effect.

**Maintenance**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**In titrating to clinical effect, allow approximately 2 minutes for onset of peak drug effect.**

**Drug Interactions**

**Cardiac Anesthesia:**

- Healthy Adults Less Than 55 Years of Age:
  - 5 mcg/kg/min (0.3 mg/kg/h) (see PRECAUTIONS, Drug Interactions).

**Healthy Adults Less Than 55 Years of Age:**

- Adult Patients: Doses of 25 to 100 mcg/kg/min may be administered in adults who require general surgery. The approved dosages should be administered when changes in core temperature are anticipated to 100 mcg/kg/min (no bolus) (see PRECAUTIONS, Drug Interactions).

**Low-Dose propofol injectable emulsion with Primary Opioid – 50 to 100 mcg/kg/min**

**Administration should not exceed 4 mg/kg/hour unless the benefits outweigh the risks (see PRECAUTIONS, Drug Interactions).**

** tempo: 50 to 100 mcg/kg/min**

**Preinduction**

- Allow approximately 2 minutes for onset of peak drug effect.

**Maintenance**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**DOSAGE AND ADMINISTRATION**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**Induction**

- Induction 0.5 to 1.5 mg/kg over 60 sec

**Preinduction**

- Allow approximately 2 minutes for onset of peak drug effect.

**Maintenance**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**In titrating to clinical effect, allow approximately 2 minutes for onset of peak drug effect.**

**Drug Interactions**

**Cardiac Anesthesia:**

- Healthy Adults Less Than 55 Years of Age:
  - 5 mcg/kg/min (0.3 mg/kg/h) (see PRECAUTIONS, Drug Interactions).

**Healthy Adults Less Than 55 Years of Age:**

- Adult Patients: Doses of 25 to 100 mcg/kg/min may be administered in adults who require general surgery. The approved dosages should be administered when changes in core temperature are anticipated to 100 mcg/kg/min (no bolus) (see PRECAUTIONS, Drug Interactions).

**Low-Dose propofol injectable emulsion with Primary Opioid – 50 to 100 mcg/kg/min**

**Administration should not exceed 4 mg/kg/hour unless the benefits outweigh the risks (see PRECAUTIONS, Drug Interactions).**

** tempo: 50 to 100 mcg/kg/min**

**Preinduction**

- Allow approximately 2 minutes for onset of peak drug effect.

**Maintenance**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**DOSAGE AND ADMINISTRATION**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**Induction**

- Induction 0.5 to 1.5 mg/kg over 60 sec

**Preinduction**

- Allow approximately 2 minutes for onset of peak drug effect.

**Maintenance**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**In titrating to clinical effect, allow approximately 2 minutes for onset of peak drug effect.**

**Drug Interactions**

**Cardiac Anesthesia:**

- Healthy Adults Less Than 55 Years of Age:
  - 5 mcg/kg/min (0.3 mg/kg/h) (see PRECAUTIONS, Drug Interactions).

**Healthy Adults Less Than 55 Years of Age:**

- Adult Patients: Doses of 25 to 100 mcg/kg/min may be administered in adults who require general surgery. The approved dosages should be administered when changes in core temperature are anticipated to 100 mcg/kg/min (no bolus) (see PRECAUTIONS, Drug Interactions).

**Low-Dose propofol injectable emulsion with Primary Opioid – 50 to 100 mcg/kg/min**

**Administration should not exceed 4 mg/kg/hour unless the benefits outweigh the risks (see PRECAUTIONS, Drug Interactions).**

** tempo: 50 to 100 mcg/kg/min**

**Preinduction**

- Allow approximately 2 minutes for onset of peak drug effect.

**Maintenance**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**DOSAGE AND ADMINISTRATION**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**Induction**

- Induction 0.5 to 1.5 mg/kg over 60 sec

**Preinduction**

- Allow approximately 2 minutes for onset of peak drug effect.

**Maintenance**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**In titrating to clinical effect, allow approximately 2 minutes for onset of peak drug effect.**

**Drug Interactions**

**Cardiac Anesthesia:**

- Healthy Adults Less Than 55 Years of Age:
  - 5 mcg/kg/min (0.3 mg/kg/h) (see PRECAUTIONS, Drug Interactions).

**Healthy Adults Less Than 55 Years of Age:**

- Adult Patients: Doses of 25 to 100 mcg/kg/min may be administered in adults who require general surgery. The approved dosages should be administered when changes in core temperature are anticipated to 100 mcg/kg/min (no bolus) (see PRECAUTIONS, Drug Interactions).

**Low-Dose propofol injectable emulsion with Primary Opioid – 50 to 100 mcg/kg/min**

**Administration should not exceed 4 mg/kg/hour unless the benefits outweigh the risks (see PRECAUTIONS, Drug Interactions).**

** tempo: 50 to 100 mcg/kg/min**

**Preinduction**

- Allow approximately 2 minutes for onset of peak drug effect.

**Maintenance**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**DOSAGE AND ADMINISTRATION**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**Induction**

- Induction 0.5 to 1.5 mg/kg over 60 sec

**Preinduction**

- Allow approximately 2 minutes for onset of peak drug effect.

**Maintenance**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.

**In titrating to clinical effect, allow approximately 2 minutes for onset of peak drug effect.**

**Drug Interactions**

**Cardiac Anesthesia:**

- Healthy Adults Less Than 55 Years of Age:
  - 5 mcg/kg/min (0.3 mg/kg/h) (see PRECAUTIONS, Drug Interactions).

**Healthy Adults Less Than 55 Years of Age:**

- Adult Patients: Doses of 25 to 100 mcg/kg/min may be administered in adults who require general surgery. The approved dosages should be administered when changes in core temperature are anticipated to 100 mcg/kg/min (no bolus) (see PRECAUTIONS, Drug Interactions).

**Low-Dose propofol injectable emulsion with Primary Opioid – 50 to 100 mcg/kg/min**

**Administration should not exceed 4 mg/kg/hour unless the benefits outweigh the risks (see PRECAUTIONS, Drug Interactions).**

** tempo: 50 to 100 mcg/kg/min**

**Preinduction**

- Allow approximately 2 minutes for onset of peak drug effect.

**Maintenance**

- 10 to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 to 50 mcg/kg/min and adjusted according to clinical responses.